Euroscicon Events

The Controlling Cancer Summit 2016: 17th – 19th May 2016

Off
Cancer2016Banner

 The annual Controlling Cancer Summit is an international academic event with plenty of opportunity for networking and debate.


 Agend    Abstract book

In an informal setting, this meeting will bring you up to date with current research and thinking regarding screening, prevention and treatment in this ever-growing field. Presenting at this event, we will have a variety of clinicians, academics and members of the pharmaceutical industry; we encourage presentations from the wide spectrum of cancer research, development and healthcare professionals.


Deadlines

  • The Deadline for abstract submissions for oral presentation is 10th February 2016
  • The early registration deadline is 20th March 2016
  • The Deadline for poster submission is 3rd May 2016

Who Should Attend:  This innovative and stimulating event is aimed at those working in research and development of drugs, industry partners, academia, biotechnology, diagnostic, clinicians and postgraduate students.


Register now for this Euroscicon Event


Talks Include

TalkSpeakerAffiliationCountry
Dendritic cell derived exosomes for cancer therapyAssociate Professor Susanne GabrielssonKarolinska InstitutetSweden
New therapeutic approaches and repurposed drugs for targeting of glioma stem cells and treatment of glioblastomaProfessor Chaya BrodieHermelin Brain Tumor CenterUnited States
The antitumor activity of cannabinoids in colorectal cancerDr David MeiriTechnion-Israel Institute of TechnologyIsrael
The stress protein TP53INP1 plays a tumor suppressive role by regulating metabolic homeostasisDr. Alice CarrierCancer Research Center of Marseille (CRCM)France
NQO1, GSTM1, and GSTT1 genetic polymorphisms and the risk of developing cancer among FilipinosDr Pia Marie AlbanoResearch Center for the Natural and Applied SciencesPhilippines
DNA damage repair and p53 gene in platinum-drug resistanceDr Jing Jie YuMary Babb Randolph Cancer CenterUnited States
Using chemical and biological data for targeted compound selection and biomarker discovery in cancer and beyond
Dr Andreas BenderUniversity of CambridgeUnited Kingdom
DNA repair gene polymorphisms as risk factors and chemotherapy response predictors for lung adenocarcinoma in SerbiaIvana BoljevicLaboratory for Molecular Genetics,Institute for Oncology and Radiology of SerbiaSerbia
CYP3A variation, hormone levels, breast cancer risk and prognosisDr Olivia FletcherGenetic Epidemiology The Institute of Cancer ResearchUnited Kingdom
Omics biomarkers and their implication in cancer controlDr Mukesh VermaNational Institutes of Health (NIH)United States
p53 regulates miRNA-AGO2 association to control miRNA-mediated post-transcriptional gene repression in cancerDr Leandro CastellanoImperial College LondonUnited Kingdom
Targeting non death domain-containing TNFR family members for cancer therapy: direct, carcinoma cell-specific death by CD40 signallingDr Nikolaos GeorgopoulosUniversity of HuddersfieldUnited Kingdom
Non-Natural Nucleosides as Therapeutic Agents Against GlioblastomaDr Anthony J. BerdisCleveland State UniversityUnited States
Nucleosomics®- Revolutionising Cancer DiagnosticsDr Mark EcclestonVolitionRxUnited Kingdom
Cancer resistance to photodynamic therapyDr. Marek MuriasPoznan University of Medical SciencesPoland
IV Iron in Anemia of Oncology, Inflammation, and other disorders of Iron deficiencyDr David HenryUniversity of PennsylvaniaUnited States
DNA methylation in epithelial-to-mesenchymal transitionDr Bozena SmolkovaSlovak Academy of SciencesSlovakia
Adoptive T cell Therapy for CancerDr David Edward GilhamThe University of ManchesterUnited Kingdom
Crosstalk between cell death modalities as anticancer targetDr Marc DiederichSeoul National UniversityKorea
Targeted nanomedicines in cancer therapyDr Christine DufesUniversity of Strathclyde

United Kingdom
Signalling therapy for cancer: from target proteins to target signalling networks Dr Alexey GoltsovUniversity of Abertay DundeeUnited Kingdom
Stem Cell based Therapies for Cancer: Mechanism and Translation into ClinicsDr. Khalid ShahHarvard Medical SchoolUnited States
DNA methylation in early detection and risk prediction of women specific cancersProfessor Martin WidschwendterInstitute for Women´s HealthUnited Kingdom
Cognitive impairment in patients with glioblastoma: single institution experienceDr. Ana Misir KrpanUniversity Hospital Center ZagrebCroatia
Precious metals for cancer treatment - a novel approach
Isolda RomeroUniversity of WarwickUnited Kingdom
Molecular factors associated with resistance to drugs targeting BRAF in malignant melanomaDr Suzanne Egyházi BrageDepartment of Oncology-PathologySweden
Responsive lanthanide complexes for imaging of key cell cycle regulators and inhibition of tumor cellsDr. Gary Ka-Leung WongHong Kong Baptist UniversityHong Kong
Immunotherapy for cancer dormancyDr. Masoud H. ManjiliVCU School of MedicineUnited States
RAD18 is involved in the resistance of glioblastoma cancer stem cells to the therapy.Dr Chames KermiGenome Surveillance and Stability Laboratory, Institute of Human Genetics (IGH)France
Recognition of LINE-1 derived DNA by the cGAS-STING pathway leads to inflammation in Fanconi AnemiaDr. Jessica GuerraCNRSMontpellier, France
Adoptive T cell Therapy for Cancer Dr.Gray KueberuwaUniversity of ManchesterUnited Kingdom
TBCDr Kenneth J. HsuKenneth Hsu Center of Cancer StudiesUnited Kingdom


Advisory Board Members

MemberAffiliationCountry
Dr Hendrik-Tobias ArkenauSarah Cannon Research Institute UKUnited Kingdom
Professor Rui Amaral Mendes
Case Western Reserve University
United States
Professor Anthony Miller
University of Toronto
Canada
Dr Alenka FokterCelje General HospitalSlovenia
Dr. Xiaoyan JiangBC Cancer Agency and University of British ColumbiaCanada
Professor Shimon SlavinThe International Center for Cell Therapy & Cancer Immunotherapy (CTCI)Israel


The Controlling Cancer Summit 2016 has an open abstract session:  Abstracts can be submitted on any subject related to cancer


CPD Credits


Related Past Agendas

ControllingCancer2015-agendathe2014controllingcancersummit-agenda

Contact

Email:  enquiries [@] euroscicon.com

Phone: (+44) 020 7183 82 31

Registration Fee

Registration includes entry to all the event, lunch and all refreshments, networking opportunities and access to exhibitions.

FEE  FOR  THREE  DAYS

 

REGISTRATION FEE

 LATE REGISTRATION FEE

Standard

£534 (£445 + VAT)

£654 (£545 + VAT)

Academic

£354 (£295 + VAT)

£474 (£395 + VAT)

Student

£234  (£195 + VAT)

£354 (£295 + VAT)

If you do not want to attend the full three days you can also book single days at the following price

 

REGISTRATION FEE

 LATE REGISTRATION FEE

Standard

£234  (£195 + VAT)

£330  (£275 + VAT)

Academic

£150  (£125 + VAT)

£234  (£195 + VAT)

Student

£114  (£95 + VAT)

£174   (£145 + VAT)

Please note: As our services are held in the UK we are obliged to charge VAT even if you are coming from outside the UK

Discounted Group Bookings

If 3 or more people register together, then you will receive a discount of £20.00 off for each person in the group

These discounts are applied automatically on registration

Bursary applications

Euroscicon will consider all applications for bursaries to cover registration, food and refreshments on the day of an event, however these are limited.  We cannot, at this time award money for travel or accommodation.  To download an application form see www.euroscicon.com/Bursary.docx

Venue, Accommodation and Travel Details

This event will be held at Cineworld: The O2 Peninsula Square London SE10 0DX United Kingdom

www.TheO2.co.uk

Once inside the O2 building please make your way to Cineworld.  A map of the O2 can be found by clicking here

For more detailed travel information click here

For accommodation suggestions click here

Map

Abstract and Poster Presentations

All abstracts accepted for oral presentation are also automatically accepted for poster presentation

INSTRUCTIONS

Payment Instructions

Payment must be received prior to the meeting

Credit card
You can pay during your online registration using your credit card. Using this mode of payment you can guarantee that your fee has reached us prior to the conference and you will be listed as registered

Paypal
You can either use your Paypal account or click on the no account link to pay directly by credit or debit card

The information taken will be by secure server.

We do not store credit card details nor do we share customer details with any 3rd parties

If you wish to pay by cheque, purchase order or bank transfer, please contact sales [@] euroscicon.com

Cancellation Policy

Please note that we must receive payment in full before the meeting.

Delegates cancelling their registration at any point up to 2 months before the event will receive a full refund minus a £20.00 admin fee.

Delegates cancelling their registration at any point between 2 months and two weeks before the meeting will receive a 50% refund.

Delegates cancelling their registration two weeks before a meeting WILL NOT receive a refund.

Substitution of delegates can be made at any time through the registration system.

If you have not paid for a meeting that you have registered for and do not come (and do not provide 2 weeks notice of cancellation), you will be charged the full price of the meeting.

This will be a paperless meeting

Untitled Document
Please print out the agenda before you come or download the pdf onto your computer or smartphone.  
Pdfs of our agendas and abstract books can be found at www.lifescienceevents.com/events 

Recent Euroscicon Event Pictures

    Euroscicon Meeting Feedback